|
| Author (year) | Diagnosis | Sample sizes (M/F) | Age (year) | Randomized method | Interventions | Acupoint selection of experimental group | Course of treatment | Outcome measures |
|
| Fan et al. (2001) [11] | Malignant tumor | E:22, C:18 | Not reported | Not reported | E: hydroacupuncture with astragalus injection 4 ml, once a day, 6 days/session | Zusanli (ST36) | Three sessions | The number of leukocyte and immunoglobulin |
| C: Batyl alcohol100 mg, leucogen 20 mg, three times a day, orally, 6 days/session | Sanyinjiao (SP6) |
|
| Ma (2016) [12] | Malignant tumor | E:4 (27/21) C:48 (28/20) | E:48.23 ± 10.35 | Random number table method | E: acupoint injection with Shenfu injection, once a day | Zusanli (ST36) | One day before chemotherapy, until the end of chemotherapy | The bone marrow suppression, changes of immune system and quality of life |
| C:60.58 ± 10.73 | C: no further treatment |
|
| Nan (2014) [13] | Gastric cancer | E:30 (13/17) | E:63.8 ± 1.8 | Not reported | E: acupoint injection with astragalus injection, once a day, 10 days/session | Zusanli (ST36) | From the day before chemotherapy to the day after chemotherapy | The bone marrow suppression, gastrointestinal toxicity |
| C:30 (19/11) | C:63.3 ± 1.3 | C: conventional treatment |
|
| Wu et al. (2014) [14] | Tumor | E:30 | Not reported | Random number table method | E: acupoint injection with astragalus injection, once every other day | Zusanli (ST36) | For 21 days | The incidence of nausea and vomiting, white blood cell and platelet count |
| C:30 | C: no further treatment |
|
| Wu and Ji (2013) [15] | Lung cancer | E:30（20/10） | E:63.7 ± 5.2 | Random number table method | E: acupoint injection of droperidol | Neiguan (PC6) | Not reported | The chemotherapy response, KPS score and quality of life |
| C:30（19/11） | C:62.5 ± 5.4 | C: no further treatment |
|
| Zhang et al. (2018) [16] | Nonsmall cell lung cancer | E:40 | Not reported | Not reported | E: acupoint injection with metoclopramide dihydrochloride injection 10 mg, once a day | Zusanli (ST36) | Not reported | The bone marrow suppression, gastrointestinal toxicity |
| C:40 | C: no further treatment |
|
| Nie (2016) [17] | Malignant tumor | E:42（23/19） | Not reported | Random double blind method | E: acupoint injection with astragalus injection 2 ml/point, once a day, 7 days | Zusanli (ST36) | Not reported | Thrombocytopenia, chills and fever, headache, fatigue, muscle soreness |
| C:42（20/22） | C: subcutaneous injection with recombinant human granulocyte colony-stimulating factor injection 150ug, once a day, 7 days | Xuehai (SP10) |
|
| Yang (2008) [18] | Malignant tumor | E:39（20/19） | Not reported | Random double blind method | E: acupoint injection with dexamethasone 5 mg, once a day, 5 days | Zusanli (ST36) | Not reported | Thrombocytopenia, chills and fever, headache, fatigue, muscle soreness |
| C:38（19/19） | C: subcutaneous injection with rhG-CSF, once a day, 3–5 days |
| M, male; F, female; E, experimental group; C, control group; rhG-CSF, recombinant human granulocyte colony-stimulating factor |
|
